

Special Issue

Clinical Applications of Tumor Immunotherapy

Message from the Guest Editors

The advent of tumor immunotherapy had a significant impact on the treatment landscape of several hematological and solid tumors. The use of immune checkpoint inhibitors (ICIs) is by far the strategy with the most dramatic impact and widest adoption in tumor immunotherapy. These agents block inhibitory interactions between cancer and immune cells, thus prompting antitumor immunity and averting tumor evasion of the immune response...Irrespective of the type considered, tumor immunotherapies yielded unprecedented benefits in hard-to-treat tumors in terms of long-lasting responses and the prolongation of survival outcomes, with a peculiar toxicity profile that can be insidious. Research on tumor immunotherapy is brisk and active, currently focusing on how to increase the proportion of patients that benefit from different immunotherapy approaches and on identifying predictive biomarkers of response; thus, it is critical to understand how available evidence and findings, as well as future perspectives, translate into resources for clinical practice.

Guest Editors

Dr. Giuseppe Lamberti

Department of Specialized, Experimental and Diagnostic Medicine,
S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

Dr. Elisa Andrini

Department of Specialized, Experimental and Diagnostic Medicine,
S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

Deadline for manuscript submissions

closed (16 September 2024)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



mdpi.com/si/179052

Journal of Clinical Medicine
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 5.7
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.3 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).